1. Scrip
  2. >>Business
  3. >>Strategy

UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges

 
• By Lucie Ellis-Taitt

UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.

Business development idea and developing industry success through creative invention as a light bulb evolving to a gear shape as a 3D illustration.
UCB shifts gears: head of strategy and BD chats to Scrip about expectations for the Belgian pharma • Source: Shutterstock

Alexander Moscho, who joined UCB Group in late 2017 from Bayer AG, told to Scrip in an exclusive interview that the Belgian firm was ready for significant deal making to add complementary technologies to its strong in-house pipeline. He also revealed his thoughts on his new role and highlighted qualities that could set UCB apart from its pharma peers as pressures increase on drug developers to show the value of their medicines.

Moscho, who was previously general manager for Bayer UK & Ireland, was attracted to UCB because of the company's clear focus on patient value and its busy pipeline that the company has recently been promoting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.